GILD — Gilead Sciences, Inc.
$156.04-0.73%
Last close: · regular session
Last 60 sessions
GILD closed at $156.04 (-0.73%) on Oct 23, 2026. Active automatic shelf (S-3ASR, Aug 2026). Float: 1.2B shares. Latest SEC filing: S-3ASR on Aug 6, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for GILD in the TickerWise workspace.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Country: US
- Exchange: NASDAQ
- Employees: 17,600
- Website: https://www.gilead.com
Latest SEC filings for GILD
Latest GILD news
- Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy? Read article
- Gilead in $45M settlement with Texas over alleged Medicaid kickback scheme Read article
- Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Read article
- Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note Read article
- All You Need to Know About Gilead (GILD) Rating Upgrade to Buy Read article
- Gilead hits mid-stage trial success for oral bowel disease therapy Read article
- Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow? Read article
- Gilead Sciences (GILD) Rises Higher Than Market: Key Facts Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.